Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operations, and a focus in oncology and hematology.
Our primary strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to an efficient in-house clinical development organization with regulatory and data management capabilities, Spectrum has established a commercial infrastructure for its marketed products. Currently, we have six oncology/hematology products on the market that target different types of non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, a type of acute lymphoblastic leukemia (ALL) and multiple myeloma.
Spectrum also has two drugs in late stage development:
SPI-2012, being developed for chemotherapy-induced neutropenia in patients with breast cancer.
Apaziquone being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer.
Our passion to identify, develop and deliver important options for patients suffering from cancer is behind every action we take. At Spectrum, we are committed to excellence and strive to make a difference in the lives of patients every day.